TNF and uveitis: Finally, a French case series showed that development of new-onset uveitis in patients receiving anti-TNFα therapy for rheumatic diseases was higher with etanercept compared with adalimumab or infliximab [22]; in our case, the possibility that etanercept could have triggered anterior chamber ocular activity cannot be excluded.